Skip to main content Skip to navigation
BUV395 Mouse Anti-Human FcεR1α
Product Details
Down Arrow Up Arrow


BD OptiBuild™
FCE1A; FCER1A; Fc-epsilon RI-alpha; FcERI; FceR1a; FcεRI
Human (Tested in Development)
Mouse IgG2b, κ
Recombinant Extracellular Domain of FcεR1α
Flow cytometry (Qualified)
0.2 mg/ml
AB_2872245
Aqueous buffered solution containing ≤0.09% sodium azide.
RUO


Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BUV395 under optimal conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions.  More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).

Product Notices

  1. This antibody was developed for use in flow cytometry.
  2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  3. Researchers should determine the optimal concentration of this reagent for their individual applications.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
  7. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
  8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  9. BD Horizon Brilliant Ultraviolet 395 is covered by one or more of the following US patents: 8,158,444; 8,575,303; 8,354,239.
747781 Rev. 1
Antibody Details
Down Arrow Up Arrow
AER-37

The AER-37 (CRA-1) monoclonal antibody specifically recognizes FcεRIα which is also known as the high affinity immunoglobulin epsilon receptor subunit alpha (Fc-epsilon RI-alpha). FcεRIα is a type I transmembrane glycoprotein that is encoded by FCER1A (Fc fragment of IgE receptor Ia) which belongs to the Ig gene superfamily. FcεRIα serves as the binding subunit for the Fc region of IgE. It forms part of a heterotetrameric, high-affinity IgE Fc receptor (FceR1/FcεR1) that includes signal transducing subunits, one β-chain (FcεRIβ encoded by MS4A2) and two disulfide-linked γ-subunits (FcεRIγ encoded by FCER1G).  FcεRIα is normally expressed on basophils and mast cells and can also be expressed on some monocytes, Langerhans cells, dendritic cells, and eosinophils from allergic donors. FcεRIα plays a major role in allergic responses and in the presentation of allergens to the immune system. The AER-37 antibody reportedly does not compete with IgE for FceR1 binding.

The antibody was conjugated to BD Horizon™ BUV395 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye has been exclusively developed by BD Biosciences to have minimal spillover into other detectors, making it an optimal choice for multicolor flow cytometry. With an Ex Max at 348 nm and an Em Max at 395 nm, BD Horizon BUV395 can be excited with a 355 nm laser and detected with a 379/28 filter.

747781 Rev. 1
Format Details
Down Arrow Up Arrow
BUV395
The BD Horizon Brilliant™ Ultraviolet 395 (BUV395) Dye is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This base dye is a polymer fluorochrome with an excitation maximum (Ex Max) of 348-nm and an emission maximum (Em Max) at 395-nm. Driven by BD innovation, BUV395 is designed to be excited by the ultraviolet laser (355-nm) and detected using an optical filter centered near 380-nm (e.g., 379/28-nm bandpass filter). BUV395 is the ideal dye when using only one detector on the ultraviolet laser as it spills into no other detectors and no other fluors spill into it. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
altImg
BUV395
Ultraviolet 355 nm
348 nm
395 nm
747781 Rev.1
Citations & References
Down Arrow Up Arrow
View product citations for antibody "747781" on CiteAb

Development References (3)

  1. Cheng YX, Foster B, Holland SM, et al. CD2 identifies a monocyte subpopulation with immunoglobulin E-dependent, high-level expression of Fc epsilon RI.. Clin Exp Allergy. 2006; 36(11):1436-45. View Reference
  2. Hasegawa S, Pawankar R, Suzuki K, et al. Functional expression of the high affinity receptor for IgE (FcepsilonRI) in human platelets and its' intracellular expression in human megakaryocytes.. Blood. 1999; 93(8):2543-51. View Reference
  3. Takai T, Yuuki T, Iwamoto-Yasue N, Okumura K, Ra C. Epitope analysis and primary structures of variable regions of anti-human FcepsilonRI monoclonal antibodies, and expression of the chimeric antibodies fused with human constant regions.. Biosci Biotechnol Biochem. 2000; 64(9):1856-67. View Reference
747781 Rev. 1

 

Please refer to Support Documents for Quality Certificates


Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described


Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.